

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SINO BIOPHARMACEUTICAL LIMITED**

**中國生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

*Website: [www.sinobiopharm.com](http://www.sinobiopharm.com)*

**(Stock code: 1177)**

## **INSIDE INFORMATION**

### **PROPOSED ISSUE OF RMB SHARES AND**

### **LISTING ON THE SCI-TECH BOARD OF THE SHANGHAI STOCK EXCHANGE**

This announcement is made by Sino Biopharmaceutical Limited (the “**Company**”) pursuant to Rule 13.09(2) of the Hong Kong Listing Rules and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of the Hong Kong).

The Company is pleased to announce that, on 3 February 2021, the Board has approved a preliminary proposal for the possible issue of RMB Shares and listing on the Science and Technology Innovation Board of the Shanghai Stock Exchange (the “**Sci-Tech Board**”) (the “**Proposed Domestic Issue**”). The Proposed Domestic Issue shall be conditional upon and subject to market conditions, the approval of the Shareholders at the general meeting of the Company and the necessary Regulatory Approvals.

The preliminary plan of the Proposed Domestic Issue is detailed as follows:

Type of securities of the Proposed Domestic Issue	The RMB Shares shall be the ordinary Shares to be subscribed in RMB by target subscribers, listed on the Sci-Tech Board and traded in RMB. Such RMB Shares shall also be in the same class of shares as the Hong Kong Shares.
--	---

Size of the Proposed Domestic Issue      The RMB Shares to be issued under the Proposed Domestic Issue shall not exceed 10% of the aggregate of the total number of Hong Kong Shares immediately prior to such issue and the number of RMB Shares contemplated under the Proposed Domestic Issue. In compliance with the applicable laws and regulations of the PRC, an over-allotment option may be granted in respect of such number of RMB Shares not exceeding 15% of that initially issued. The RMB Shares will all be newly issued Shares, and no conversion of the existing Shares will be involved.

The final issue size of the RMB Shares shall be agreed and determined by the Board as authorised by the general meeting of the Company and the sponsor(s) and underwriter(s) subject to the issue size registered with the relevant securities regulatory authorities, the Company's needs and market conditions.

Preliminary use of proceeds      After deducting the issuance expenses, the proceeds of the Proposed Domestic Issue are preliminarily intended to be used for the development of the principal businesses of the Company, merger and acquisition in the industry, and general working capital.

Place of listing of RMB Shares      The Sci-Tech Board.

As of the date of this announcement, save and except for the information disclosed herein, the Board has neither approved other plans in relation to the Proposed Domestic Issue, nor made any application to the relevant regulatory authorities in the PRC or any other regions in respect of the Proposed Domestic Issue.

**Shareholders and potential investors should note that the concrete plan of the Proposed Domestic Issue shall be subject to further approval of the Board and the general meeting of the Company, as well as the Regulatory Approvals, thus may or may not be implemented. Shareholders and potential investors of the Company should be aware that there is no assurance that the Proposed Domestic Issue will materialise or as to when it may materialise. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares.**

**Further announcements will be made by the Company in accordance with the Hong Kong Listing Rules and other applicable laws and regulations on any material updates and progress in connection with the Proposed Domestic Issue as and when appropriate. This announcement is for information purposes only and does not constitute any invitation or offer to acquire, purchase or subscribe for the Shares of the Company.**

## DEFINITIONS

In this announcement, the following expressions have the following meanings unless the context requires otherwise:

“Board”	the board of Directors
“CSRC”	the China Securities Regulatory Commission
“Directors”	directors of the Company
“Hong Kong”	the Hong Kong Special Administrative Region of the People’s Republic of China
“Hong Kong Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (as amended from time to time)
“Hong Kong Shares”	Shares in issue for the time being which are listed on the Hong Kong Stock Exchange
“Hong Kong Stock Exchange”	The Stock Exchange of Hong Kong Limited
“PRC”	the People’s Republic of China
“Regulatory Approvals”	the approvals or decisions made by the relevant regulatory authorities and governmental departments of the PRC, Hong Kong, and the Cayman Islands (if applicable) (including but not limited to the CSRC, the Hong Kong Stock Exchange and the Shanghai Stock Exchange)
“RMB”	Renminbi, the lawful currency of the PRC
“RMB Shares”	Shares to be subscribed for in RMB by target subscribers in the PRC, listed on the Sci-Tech Board and traded in RMB
“Shareholders”	holders of the Shares
“Shares”	ordinary shares of nominal value of HK\$0.025 each in the share capital of the Company

By order of the Board  
**Sino Biopharmaceutical Limited**  
**Tse, Theresa Y Y**  
*Chairwoman*

Hong Kong, 3 February 2021

*As at the date of this announcement, the Board of the Company comprises nine Executive Directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and five Independent Non-Executive Directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Mr. Li Kwok Tung Donald.*